Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 1
1993 2
1994 1
1995 2
1996 3
1997 3
1998 1
1999 2
2000 3
2001 7
2002 11
2003 9
2004 12
2005 9
2006 12
2007 4
2008 6
2009 11
2010 6
2011 8
2012 7
2013 5
2014 7
2015 3
2016 5
2017 4
2018 4
2019 5
2020 7
2021 1
2022 3
2023 2
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Homoharringtonine is a transdermal granular permeation enhancer.
Watari A, Fujiwara K, Yagi K, Tachibana K, Katsurada T, Myoui A, Kondoh M. Watari A, et al. Among authors: myoui a. Biochem Biophys Res Commun. 2022 Aug 6;616:140-144. doi: 10.1016/j.bbrc.2022.04.067. Epub 2022 Apr 18. Biochem Biophys Res Commun. 2022. PMID: 35679696
Trabectedin is a promising antitumour agent for synovial sarcoma.
Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N. Yasui H, et al. Among authors: myoui a. J Chemother. 2016 Oct;28(5):417-24. doi: 10.1080/1120009X.2015.1133013. Epub 2016 Jan 29. J Chemother. 2016. PMID: 27077926
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.
Kiyohara E, Tanemura A, Sakura K, Nakajima T, Myoui A, Yamazaki N, Kiyohara Y, Katayama I, Fujimoto M, Kaneda Y. Kiyohara E, et al. Among authors: myoui a. Cancer Immunol Immunother. 2022 Aug;71(8):2041-2049. doi: 10.1007/s00262-021-03122-z. Epub 2022 Jan 5. Cancer Immunol Immunother. 2022. PMID: 34984539 Free PMC article. Clinical Trial.
A novel type of EWS-CHOP fusion gene in myxoid liposarcoma.
Matsui Y, Ueda T, Kubo T, Hasegawa T, Tomita Y, Okamoto M, Myoui A, Kakunaga S, Yasui N, Yoshikawa H. Matsui Y, et al. Among authors: myoui a. Biochem Biophys Res Commun. 2006 Sep 22;348(2):437-40. doi: 10.1016/j.bbrc.2006.07.085. Epub 2006 Jul 28. Biochem Biophys Res Commun. 2006. PMID: 16884691
[p38 MAP Kinase inhibitor].
Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Nishikawa M, et al. Among authors: myoui a. Nihon Rinsho Meneki Gakkai Kaishi. 2007 Oct;30(5):390-7. doi: 10.2177/jsci.30.390. Nihon Rinsho Meneki Gakkai Kaishi. 2007. PMID: 17984579 Free article. Review. Japanese.
161 results